French Observatory of Rare Malignant Tumors of the Ovary

ARCAGY/ GINECO GROUP204 enrolled

Overview

To take charge of the treatment in rare adult ovarian tumors with an homogenous manner (germinal and sexual cords tumors), at different stages of the disease.

* to establish prognosis factors for the disease * to proceed in a centralised examination of histologic laminas * to reach in the long-term and homogenous follow-up of the patients * to follow-up the long-term toxicities of the treatments given * to analyse and follow-up the later fertility of the patients * to evaluate the interest of setting a multi-disciplinary discussion forum on the Web

Study Type

OBSERVATIONAL

Enrollment

204

Conditions

Ovarian Tumors

Interventions

chemotherapies protocolsDRUG

Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age \> 18 years old * germinal or sexual cords ovary tumors histologically proven * first line or relapse treatment * written informed consent Exclusion Criteria: * mental ineptitude to understand and follow the study

Locations (1)

Oncologie, Hôtel-Dieu, 1 place du parvis Notre-Dame

Paris, France

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.